2013 Annual Meeting Archive Scientific Plenaries

2013 Annual Meeting Archive Scientific Plenaries

2013 Annual Meeting Archive > 2013 Annual Meeting Scientific Plenaries

2013 Annual Meeting Scientific Plenaries

Scientific Plenary I: Clinical Trial Advances
Scientific Plenary II: Surgical Advances
Scientific Plenary III: Novel Therapeutics and Trial Design
Scientific Plenary IV: Cancer Prevention and Beyond
Scientific Plenary V: Late-Breaking Abstract Session
Scientific Plenary VI: Health Care Outcomes: Charting the Course
Scientific Plenary VII: Clinical Practice Management Issues
Scientific Plenary VIII: Origins of Serous Cancers

2013 Annual Meeting Education Scientific Plenary Session I

Scientific Plenary Session I: Clinical Trial Advances, Abstracts 1-6

Moderators:
Allan Covens, MD, FRCSC, University of Toronto
Jonathan Ledermann, BSc, MD, FRCP, UCL Cancer Institute & UCL Hospitals

Abstract 1

Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study

K. Tewari1, M. Sill2, B. Monk3, H. Long4, L. Ramondetta5, L. Landrum6, A. Oaknin7, T. Reid8, M. Leitao9, H. Michael10

1UC Irvine Medical Center, Orange, CA, 2Roswell Park Cancer Institute, Buffalo, NY, 3St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 4Mayo Clinic, Rochester, MN, 5MD Anderson Cancer Center, Houston, TX, 6University of Oklahoma, Oklahoma City, OK, 7Hospital Vall d’Hebron, Barcelona, Spain, 8University of Cincinnati College of Medicine/Women’s Cancer Center at Kettering, Kettering, OH, 9Memorial Sloan-Kettering Cancer Center, New York, NY, 10Clarian North Medical Center, Carmel, IN

Abstract 2

Prognostic factors for stage IVB, persistent or recurrent cervical cancer (From the Results of the JCOG0505 Trial)

S. Nishio1, R. Kitagawa2, T. Shibata3, K. Ushijima1, H. Yoshikawa4, T. Kamura1

1Kurume University School of Medicine, Fukuoka, Japan, 2NTT Medical Center Tokyo, Tokyo, Japan, 3National Cancer Center, Tokyo, Japan, 4University of Tsukuba, Ibaraki, Japan

Abstract 3

A phase II evaluation of carboplatin/paclitaxel/bevacizumab in the treatment of advanced stage endometrial carcinoma

D. O’Malley, G. McCann, J. Fowler, L. Copeland, F. Backes, R. Salani, E. Eisenhauer, D. Cohn

Ohio State University, Columbus, OH

Abstract 4

Symptoms and adverse effects with chemotherapy ± bevacizumab for platinum-resistant recurrent ovarian cancer: Analysis Of The Phase Iii Aurelia Trial

F. Hilpert1, M. Fabbro2, M. Jesus Rubio3, A. Reuss4, P. Rosenberg5, P. Benedetti Panici6, P. Vuylsteke7, P. Witteveen8, F. Zagouri9, E. Pujade-Lauraine10

1AGO and University of Schleswig-Holstein Campus Kiel, Kiel, Germany, 2GINECO and CRLC Val d’Aurelle, Montpellier, France, 3GEICO and Hospital Universitario Reina Sofia de Córdoba, Córdoba, Spain, 4AGO and Universität Marburg, Marburg, Germany, 5NSGO and Linköping University Hospital, Linköping, Sweden, 6MITO and University of Rome “Sapienza”, Rome, Italy, 7BGOG and CMSE Namur, Namur, Belgium, 8DGOG and University Medical Center Utrecht, Utrecht, Netherlands, 9HECOG and General Peripheral Hospital of Athens “Alexandra”, Athens, Greece, 10GINECO and Université Paris Descartes, Paris, France

Abstract 5

Hyperthermic intraperitoneal chemotherapy following extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: Result of a pospective phase II study

M. Lim, M. Im H. Yoo, S. Seo, S. Kang, S. Park

National Cancer Center, Goyang-si, Republic of Korea

Abstract 6

Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study (GOG#114/172, abstract)

D. Tewari1, J. Java2, R. Salani3, D. Armstrong4, M. Markman5, T. Herzog6, B. Monk7, J. Chan8

1Southern California Permanente Medical Group, Los Angeles, CA, 2Gynecologic Oncology Group, Buffalo, NY, 3Ohio State University, Columbus, OH, 4Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 5Cancer Treatment Centers of America, Philadelphia, PA, 6New York Presbyterian Medical Center, New York, NY, 7Creighton University School of Medicine, Phoenix, AR, 8UCSF Comprehensive Cancer Center, San Francisco, CA

2013 Annual Meeting Education Scientific Plenary Session II

Scientific Plenary II: Surgical Advances, Abstracts 18-23

Moderators:
Michael Frumovitz, MD, The University of Texas, MD Anderson Cancer Center.
Amanda Nickles Fader, MD, Greater Baltimore Medical Center/Johns Hopkins Medical Institutions

Abstract 18

Predictive role of biology in the feasibility of optimal versus suboptimal cytoreduction in advanced serous ovarian cancer

R. Abdallah1, N. Bou Zgheib, I. Ramirez-Diaz, S. Apte, P. Judson Lancaster, R. Wenham, W. Roberts, J. Lancaster, J. Gonzalez Bosquet

H. Lee Moffitt Cancer Center, Tampa, FL

Abstract 19

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? A Gynecologic Oncology Group ancillary data study

B. Rungruang1, A. Miller2, T. Krivak3, N. Horowitz4, N. Rodriguez5, C. Hamilton6, M. Bookman7, G. Maxwell8, S. Richard9

1Georgia Health Sciences University, Augusta, GA, 2Gynecologic Oncology Group Statistical Data Center, Buffalo, NY, 3Magee-Womens Hospital of UPMC, Pittsburgh, PA, 4Brigham & Women’s Hospital, Boston, MA, 5Loma Linda University Medical Center, Loma Linda, CA, 6Walter Reed Army Medical Center, Washington, DC, 7University of Arizona, Tucson, AZ, 8Inova Fairfax Hospital Women’s Center, Fairfax, VA, 9Hahnemann University Hospital, Philadelphia, PA

Abstract 20

Phase II trial of robotic cyberknife radiation therapy in patients with recurrent gynecological malignancies

C. Kunos, J. Brindle, S. Singh, G. Pettigrew, R. DeBernardo

Case Western Reserve – Mac Donald Women’s Hospital, Cleveland, OH

Abstract 21

Lymphoscintigraphic detection in sentinel node biopsy for early cervical cancer: Results of the SENTICOL study

A. Bats1, A. Frati1, P. Mathevet2, D. Querleu3, E. Leblanc4, P. Morice5, E. Daraï6, H. Marret7, F. Lecuru8

1Hôpital Européen Georges-Pompidou, Paris, France, 2Hôpital Mère-Enfants, Bron, France, 3Institut Claudius Regaud, Toulouse, France, 4Centre Oscar Lambret, Lille, France, 5Institut Gustave Roussy, Villejuif, France, 6Hôpital Tenon, Paris, France, 7CHU Bretonneau, Tours, France, 8Georges Pompidou European Hospital, Paris, France

Abstract 22

Sentinel Lymph node mapping: A valuable tool for assessing nodal metastasis in low grade endometrial cancer with superficial myoinvasion

C. Kim, F. Khoury-Collado, E. Barber, R. Soslow, V. Makker, M. Leitao, Y. Sonoda, D. Chi, R. Barakat, N. Abu-Rustum

1Memorial Sloan-Kettering Cancer, New York, NY

Abstract 23

Detection of sentinel Lymph nodes using indocyanine green and near-infrared fluorescence imaging for gynecological malignancies

E. Jewell, J. Juan, G. Gardner, N. Abu-Rustum, C. Brown, Y. Sonoda, R. Barakat, D. Levine, M. Leitao

Memorial Sloan-Kettering Cancer Center, New York, NY

2013 Annual Meeting Education Scientific Plenary Session III

Scientific Plenary III: Novel Therapeutics and Trial Design, Abstracts 24-29

Moderators:
John Chan, MD, UCSF Comprehensive Cancer Center
Christine Walsh, MD, UCLA Cedars Sinai Medical Center

Abstract 24

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)

J. Lee, J. Hays, A. Noonan, C. Annunziata, L. Minasian, J. Zujewski, N. Houston, J. Hearn, M. Yu, E. Kohn

National Cancer Institute, Bethesda, MD

Abstract 25

A Phase-I trial of a novel autologous oxidized whole-tumor antigen vaccine therapy for recurrent ovarian cancer

J. Tanyi, L. Kandalaft, C. Chiang, G. Mantia-Smaldone, E. Zsiros, D. Powell, G. Coukos

University of Pennsylvania Medical Center, Philadelphia, PA

Abstract 26

Combination of irinotecan and bevacizumab for heavily pretreated recurrent ovarian cancer: A phase II trial

H. Ling, F. Muggia, J. Speyer, J. Curtin, S. Blank, L. Boyd, B. Pothuri, X. Li1, J. Goldberg, A. Tiersten

New York University School of Medicine, New York, NY

Abstract 27

A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

R. Coleman1, M. Sill2, P. Thaker3, K. De Geest4, D. Street5, W. McGuire6, J. Rotmensch7

1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Roswell Park Cancer Institute, Buffalo, NY, 3University of Washington School of Medicine, St. Louis, MO, 4University of Iowa Hospitals and Clinics, Iowa City, IA, 5Cancer Care Associates, Tulsa, OK, 6Walter Reed Army Medical Center, Washington, DC, 7Rush University Medical Center, Chicago, IL

Abstract 28

Phase 0 Study: Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer

P. Soliman, R. Broaddus, S. Westin, D. Iglesias, M. Munsell, R. Schmandt, J. Celestino, J. Burzawa, K. Lu

The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract 29

Endpoints in clinical trials: What do our patients consider important? A survey of the Ovarian Cancer National Alliance (OCNA)

R. Coleman1, R. Alvarez2, T. Herzog3

1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2University of Alabama at Birmingham, Birmingham, AL, 3Columbia University College of Physicians and Surgeons, New York, NY

2013 Annual Meeting Education Scientific Plenary Session IV

Scientific Plenary IV: Cancer Prevention and Beyond, Abstracts 39-44

Moderators:
Jeffrey Hines, MD, Southeastern Gynecologic Oncology at St. Joseph’s Hospital – Emory Healthcare
Joan Walker, MD, University of Oklahoma

Abstract 39

Rural-urban disparity in declining ovarian cancer mortality rates: Analysis of US death records data from 1999 to 2009

A. Melamed1, J. Rauh-Hain2, R. Clark2, L. Bradford2, A. Goodman2, M. Del Carmen2, W. Growdon2, D. Boruta2, J. Schorge2

1Massachusetts General Hospital/Brigham and Women’s Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA

Abstract 40

Black and White Women in Maryland Receive Different Treatment for Cervical Cancer

S. Temkin, S. Fleming, N. Schluterman, J. Tracy

University of Maryland, Baltimore, MD

Abstract 41

Efficacy of the Human Papillomavirus vaccination in women aged 20-45 years with High-grade Cervical Intraepithelial Neoplasia Treated by Loop Electrosurgical

S. Kim, W. Kang, H. Choi

Chonnam National University Medical School, Gwangju, Republic of Korea

Abstract 42

Cancer risk in endometrial carcinoma survivors: A longitudinal case-control study

A. Van Arsdale1, C. Qualls2, E. Conroy1, T. Ford1, E. Prossnitz2, H. Smith1

1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2University of New Mexico, Albuquerque, NM

Abstract 43

Diet-induced obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer

V. Bae-Jump1, Y. Zong1, X. Du2, L. Makowski1, W. Jia3, C. Zhou1

1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Charlotte, Charlotte, NC, 3University of North Carolina at Greensboro, Greensboro, NC

Abstract 44

Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (Succeed): A randomized controlled trial

M. McCarroll1, H. Frasure2, K. Gil3, M. Kavanagh4, S. Waggoner2, V. Von Gruenigen1

1Summa Health System, Akron, OH, 2University Hospitals Case Medical Center, Cleveland, OH, 3Northeastern Ohio Universities College of Medicine, Akron, OH, 4Case Western Reserve University, Cleveland, OH

2013 Annual Meeting Education Scientific Plenary Session V

Scientific Plenary V: Late-Breaking Abstract Session

2013 Annual Meeting Education Scientific Plenary Session VI

Scientific Plenary VI: Health Care Outcomes: Charting the Course, Abstracts 45-48

Moderators: Heidi Gray, MD, University of Washington Medical Center
Chirag Shah, MD, Pacific Gynecology Specialists

Abstract 45

NCCN treatment guidelines for ovarian Cancer: A population-based validation study of structural and process quality measures

R. Bristow, J. Chang, A. Ziogas, H. Anton-Culver

University of California Irvine – Medical Center, Orange, CA

Abstract 46

The impact of facility volume on receiving standard of care therapy for locally-advanced cervical cancer: A National Cancer Data Base study

J. Lin1, J. Berger1, T. Krivak1, S. Beriwal1, J. Chan2, P. Sukumvanich1, B. Monk3, S. Richard4

1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2UCSF Comprehensive Cancer Center, San Francisco, CA, 3Creighton University School of Medicine, Omaha, NE, 4Hahnemann University Hospital, Philadelphia, PA

Abstract 47

Pathologic and treatment outcomes among a geriatric population of endometrial cancer patients: A Gynecologic Oncology Group ancillary data study

E. Bishop1, J. Java2, K. Moore3, J. Walker3

1University of Oklahoma HSC, Oklahoma City, OK, 2Roswell Park Cancer Institute, Buffalo, NY, 3University of Oklahoma, Oklahoma City, OK

Abstract 48

The Affordable Care Act and its impact on the care of gynecologic oncology patients in the absence of Medicaid expansion in central Virginia

M. Courtney-Brooks1, C. Engelhard2, E. Pelkofski1, L. Duska1

1University of Virginia Health System, Charlottesville, VA, 2University of Virginia, Charlottesville, VA stern Case Western Reserve University, Cleveland, OH

2013 Annual Meeting Education Scientific Plenary Session VII

Scientific Plenary VII: Clinical Practice Management Issues, Abstracts 53-58

Moderators:
Michael Gold, MD, Tulsa Cancer Institute
Dayna McCauley, Pharm.D, BCOP, State University of New York at Stony Brook

Abstract 53

The treatment and survival differences of Asians vs. Whites with epithelial ovarian cancer

K. Fuh1, J. Shin1, K. Blansit1, T. Kiet1, R. Brooks1, L. Chen1, S. Ueda1, B. Monk2, D. Kapp3, J. Chan1

1University of California, San Francisco, San Francisco, CA, 2Creighton University School of Medicine, Phoenix, AR, 3Stanford University Medical Center, Stanford, CA

Abstract 54

Prognostic significance of ethnicity and age in advanced stage ovarian cancer: An analysis of GOG 218

N. duPont1, M. Brady1, R. Burger2, B. Monk3

1Roswell Park Cancer Institute, Buffalo, NY, 2Fox Chase Cancer Center, Philadelphia, PA, 3Creighton University School of Medicine, Omaha, NE

Abstract 55

How risky is it to operate on patients with low albumin? Analysis of the patients undergoing surgery for gynecologic cancers.

S. Uppal, A. Al-Niaimi, L. Rice, D. Kushner, K. Kudsk, E. Hartenbach

University of Wisconsin, Madison, WI

Abstract 56

Negative survival impact associated with >25 day interval from surgical cytoreduction to initiation of systemic therapy in advanced ovarian carcinoma: A Gynecologic Oncology Group ancillary data study.

R. Eskander1, J. Java2, K. Tewari1, R. Burger3, B. Monk4

1UC Irvine Medical Center, Orange, CA, 2Roswell Park Cancer Institute, Buffalo, NY, 3Fox Chase Cancer Center, Philadelphia, PA, 4Creighton University School of Medicine, Omaha, NE

Abstract 57

Survival in early stage endometrioid endometrial cancer risk groups: A Gynecologic Oncology Group ancillary data study

M. Milam1, J. Java2, L. Parker3, D. Metzinger3, R. Coleman4, J. Walker5

1Norton Cancer Institute, Louisville, KY, 2Gynecologic Oncology Group, Buffalo, NY, 3University of Louisville, Louisville, KY, 4The University of Texas, MD Anderson Cancer Center, Houston, TX, 5University of Oklahoma, Oklahoma City, OK

Abstract 58

Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin

C. Choi1, B. Kim1, M. Kim2, J. Park1, A. Yoon1, H. Kim1, Y. Lee1, T. Kim1, J. Lee1, D. Bae1

1Samsung Medical Center, Seoul, Republic of Korea, 2Samsung Medical Center, Changwon, Republic of Korea

2013 Annual Meeting Education Scientific Plenary Session VIII

Scientific Plenary VIII: Origins of Serous Cancers, Abstracts 59-62

Moderators:
Blake Gilks, University of British Columbia
Jamie Lesnock, MD, Mid Atlantic Gynecologic Oncology of Mon General Hospital

Abstract 59

A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen

R. Rocconi1, L. Pannell1, D. Billheimer2, J. Blandford1, L. Schambeau1, M. Finan1

1University of South Alabama-Mitchell Cancer Institute, Mobile, AL, 2University of Arizona, Tuscon, AZ

Abstract 60

Serous cancer precursor evolution in the fallopian tube

C. Crum1, G. Ning2, M. Herfs3, y. yamamoto4, F. McKeon5, W. Xian6

1Brigham and Women’s Hospital, Boston, MA, 2Jackson Laboratories, Farmington, United States, 3Brigham & Women’s Hospital, Boston, MA, 4A*STAR, Singapore, Singapore, 5Jackson laboratories, Farmington, CT, 6Jackson Laboratories, Farmington, CT

Abstract 61

Brush cytology of the fallopian tube

G. Linnemeier1, G. Sutton1, A. Moriarty2, M. Callahan1, H. Fornalik1, R. McCarthy2

1St. Vincent Gynecologic Oncology, Indianapolis, IN, 2St. Vincent Hospital, Indianapolis, IN

Abstract 62

The Impact of tubal sterilization techniques on the risk of serous ovarian and primary peritoneal carcinoma: A Rochester Epidemiology Project (REP) study

C. Lessard-Anderson, R. Molitor, J. St. Sauver, K. Steckelberg, A. Weaver, J. Bakkum-Gamez, S. Dowdy, B. Cliby

Mayo Clinic, Rochester, MN